

Table S1 Association between ERCC1 immunostaining results and prostate cancer phenotype in ERG-negative tumors

Parameter	n evaluable	ERCC1				p value
		negative (%)	weak (%)	moderate (%)	strong (%)	
All cancers	5,078	47.4	33.6	15.7	3.3	
Tumor stage						
pT2	3,432	49.2	33.4	14.5	2.9	<0.0001
pT3a	1,007	47.0	32.3	17.2	3.6	
pT3b-pT4	624	38.0	37.0	19.7	5.3	
Gleason grade						
≤3+3	1,050	61.0	27.1	10.4	1.5	<0.0001
3+4	2,695	48.0	34.4	14.9	2.8	
3+4 Tert.5	224	44.6	34.4	17.9	3.1	
4+3	533	36.0	36.8	21.4	5.8	
4+3 Tert.5	301	30.2	40.2	21.9	7.6	
≥4+4	271	32.8	36.9	24.4	5.9	
Lymph node metastasis						
N0	2,944	44.5	35.2	16.5	3.7	0.0025
N+	275	35.3	36.0	21.8	6.9	
Preop. PSA level (ng/ml)						
<4	533	44.8	35.3	15.4	4.5	0.1597
4-10	2,998	47.3	34.5	15.3	2.9	
10-20	1,105	48.5	31.8	16.6	3.2	
>20	399	47.9	30.8	16.0	5.3	
Surgical margin						
negative	4,042	47.6	33.9	15.4	3.0	0.0853
positive	948	45.8	32.5	17.4	4.3	

Table S2 Association between ERCC1 immunostaining results and prostate cancer phenotype in ERG-positive tumors

Parameter	n evaluable	ERCC1				p value
		negative (%)	weak (%)	moderate (%)	strong (%)	
All cancers	4,067	18.6	41.4	32.2	7.8	
Tumor stage						
pT2	2,427	20.9	42.9	29.3	6.8	<0.0001
pT3a	1,072	16.6	38.2	35.2	10.1	
pT3b-pT4	552	11.8	41.3	39.1	7.8	
Gleason grade						
≤3+3	867	26.9	41.9	25.6	5.7	<0.0001
3+4	2,307	17.8	41.5	32.6	8.1	
3+4 Tert.5	120	11.7	51.7	30.8	5.8	
4+3	399	12.3	39.6	38.1	10.0	
4+3 Tert.5	225	12.4	40.9	38.7	8.0	
≥4+4	147	12.9	36.1	40.1	10.9	
Lymph node metastasis						
N0	2,311	16.1	40.8	34.0	9.1	0.3736
N+	251	13.1	44.2	35.5	7.2	
Preop. PSA level (ng/ml)						
<4	571	20.1	44.5	28.9	6.5	0.0170
4-10	2,472	18.8	42.1	31.3	7.8	
10-20	730	18.4	37.0	36.2	8.5	
>20	245	13.5	40.4	38.0	8.2	
Surgical margin						
negative	3,184	19.5	41.9	30.9	7.6	0.0030
positive	808	15.5	39.5	36.9	8.2	